Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title
07 Nov 2007 Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
06 Nov 2007 New Galvus(R) clinical data reinforces efficacy profile; safety update provided to regulatory agencies
06 Nov 2007 CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
05 Nov 2007 MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
05 Nov 2007 Osteologix Announces Positive Phase II Study of Its Investigational Osteoporosis Drug, NB S101
05 Nov 2007 Transition Therapeutics Provides Update on Diabetes Program
05 Nov 2007 Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-IProduction Increase
31 Oct 2007 Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
31 Oct 2007 Altea Therapeutics Announces Positive Clinical Results for its Basal Insulin Transdermal Patch in Patients with Type 1 Diabetes
31 Oct 2007 Sapphire Therapeutics Licenses Ghrelin Antagonist Program from Novo Nordisk for Development of Obesity Treatments
31 Oct 2007 Apollo's oral insulin approach confirmed by US research
30 Oct 2007 EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
29 Oct 2007 Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholesterolemia
26 Oct 2007 Unigene Reports Successful Completion of Oral Calcitonin Human Study
26 Oct 2007 Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
25 Oct 2007 Anthera Announces Positive Phase II Clinical Results from A-002 Cardiovascular Disease Trial
24 Oct 2007 Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients with Urea Cycle Disorders
24 Oct 2007 Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
23 Oct 2007 Novo Nordisk receives approval for Levemir(R) in Japan (22 Oct 2007)
22 Oct 2007 Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
22 Oct 2007 OREXIGEN(TM) Therapeutics Reports Detailed Results of Phase IIb Trial of Empatic(TM) to Treat Obesity
22 Oct 2007 OREXIGEN(TM) Therapeutics Reports a Summary of Results from the Phase IIb Trial of Contrave(TM) to Treat Obesity
20 Oct 2007 Miglustat (Zavesca(R)) receives negative opinion from the European Committee for Medicinal Products for Human Use for extension of indication for Niemann Pick type C
19 Oct 2007 Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
19 Oct 2007 Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
19 Oct 2007 Nektar Therapeutics Issues Statement on Exubera
18 Oct 2007 SemBioSys confirms commercially viable levels of Native APO AI in safflower
18 Oct 2007 Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus(R)
18 Oct 2007 OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
17 Oct 2007 Hollis-Eden Pharmaceuticals Commencing Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers
16 Oct 2007 Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
16 Oct 2007 Vitae Pharmaceuticals and Boehringer Ingelheim announce a major collaboration to develop and commercialize novel treatments for diabetes and metabolic diseases
10 Oct 2007 Sciele Completes Enrollment of Patients in Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
09 Oct 2007 Metabasis Therapeutics Presents Preclinical Results for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia at the American Thyroid Association's National Meeting
09 Oct 2007 Karo Bio has presented positive KB2115 Phase II data at two international scientific congresses
09 Oct 2007 Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels
09 Oct 2007 Akesis Pharmaceuticals Files IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes
08 Oct 2007 Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
06 Oct 2007 Genzyme Receives Approval to Market Elaprase(R) in Japan
06 Oct 2007 Aclasta(R) receives European approval as first once-yearly treatment for postmenopausal osteoporosis
06 Oct 2007 Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
06 Oct 2007 AVONTEC's drug candidate AVT-02 UE for the treatment of inflammatory skin diseases has entered a multiple dosing Phase I study
06 Oct 2007 Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
05 Oct 2007 Nestle Nutrition and Phosphagenics to commence Phospha E(R) phase 2 clinical trial
05 Oct 2007 Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study
04 Oct 2007 Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
03 Oct 2007 DiaMedica Announces Exciting Phase II Results for DM-71 in Type 2 Diabetes Trial
02 Oct 2007 Kissei and Eisai sign a license agreement to develop and commercialize Glufast(R), a rapid-acting insulin secretagogue in China
02 Oct 2007 Theratechnologies Reports Positive 52-Week Phase 3 Results For Its Lead Drug Candidate Tesamorelin
02 Oct 2007 FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 351 - 400 of 1041

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics